 Dividend.com | Positive long-term results for Bristol-Myers Squibb's Nulojix in organ rejection The Pharma Letter Nulojix was approved by both US and European regulators last summer for the prevention of acute rejection in adult patients who have had a kidney transplant (The Pharma Letters June 16 and 21, 2011). The product has been forecast to achieve annual ... Bristol-Myers Squibb Presents New 4-Year Data from the Long-Term Extensions of ... |
